Skip to main content

Quest Diagnostics statistics

  • DGX · NYSE
  • Healthcare
  • Health Care Services
  • S&P 500
$259.60−0.02%Close 13 Nov 2026 · Market value $28.70B

Valuation and share-price figures are struck on the latest close (13 Nov 2026); the others are read from the company's reports. A figure that cannot be worked out, such as a P/E after a loss, is left out.

Valuation

Quest Diagnostics is valued at $28.70B on its latest close. Its price is 25.4 times its earnings.

Market value$28.70B
Enterprise value$34.45B
Price / earnings25.42
Price / sales2.42
Price / book3.76
EV / EBITDA14.93
EV / sales2.91
Price / free cash flow20.87
Price / free cash flow, own 5-year average15.92
EV / EBIT19.84
EV / free cash flow24.87
Free cash flow yield4.8%
Dividend yield1.3%

Share price

Latest close$259.60
Day's change−0.0%
52-week high$262.00
52-week low$171.18
From 52-week high−0.9%
Return · 1 month+10.5%
Return · 3 months+7.6%
Return · year to date+49.6%
Return · 1 year+38.9%
Beta · 1 year against the S&P 500−0.06
50-day average$241.30
200-day average$215.70
RSI 1469.1
Average volume · 20 sessions968K

Margins and returns

For fiscal 2025, as filed.

Gross margin33.2%
Operating margin14.1%
Net margin9.0%
Free cash flow margin12.3%
Return on equity14.2%
Return on assets7.3%
Return on invested capital8.2%
Return on invested capital, 5-year average10.2%
Return on capital employed11.1%
Stock-based compensation / revenue0.8%

Financial position

At the end of fiscal 2025.

Cash and equivalents$420.0M
Total debt$6.38B
Net debt$5.96B
Current ratio1.04
Quick ratio1.37
Debt / equity0.89
Net debt / EBITDA2.80
Interest coverage5.62

Growth

Revenue, latest quarter on a year+10.0%
Revenue, twelve months on a year+9.1%
EPS, latest quarter on a year+28.7%
EPS, twelve months on a year+17.6%
Revenue, 5-year compound+3.2%
Revenue, 10-year compound+3.9%
Net income, 5-year compound−7.1%
Free cash flow, 5-year compound−3.1%
EPS, 5-year compound−3.6%

Shares and dividends

For fiscal 2025, as filed.

Diluted shares113M
Shares outstanding, 5-year compound−3.6%
Net share repurchases$371.0M
Dividend payout35.6%

Taxes

For fiscal 2025, as filed.

Income tax expense$314.0M
Effective tax rate23.8%

DGX in the terminal

Valuation against the company's own history, a cash-flow valuation, peers, charts and alerts.